Literature DB >> 20932142

The Duke Abdominal Assessment Scale: initial experience.

Caroline L Hollingsworth1, Henry E Rice.   

Abstract

Plain abdominal radiographs are the current standard imaging modality of choice in the evaluation of patients with clinically suspected necrotizing enterocolitis. The time interval between radiographic exams varies with the severity of disease and may range from every 6 h to every 24 h. Radiographs are often also obtained at any point of acute clinical deterioration. Evaluation of the abdominal radiographic series is critical as the findings may alter patient management and can be an indication for surgical intervention. For these reasons, it is essential that the radiographic findings are communicated to the referring neonatologist in a clear and consistent manner. Inherent variability and lack of consistency in radiology reporting makes it difficult for the referring clinician to incorporate radiographic reports into his/her treatment algorithm. Assigning abdominal radiographic findings in necrotizing enterocolitis to a numerical scale that increases as the disease progresses provides objective terminology in lieu of subjective descriptors and may facilitate communication to our clinical colleagues. With this task in mind, the Duke Abdominal Assessment Scale was created as a 10-point numerical scale of plain film bowel gas pattern findings designed to reflect progressive disease and increased certainty of the diagnosis of necrotizing enterocolitis.

Entities:  

Mesh:

Year:  2010        PMID: 20932142     DOI: 10.1586/egh.10.52

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  1 in total

1.  Bowel Perforation in Premature Infants with Necrotizing Enterocolitis: Risk Factors and Outcomes.

Authors:  Lingling Yu; Jianmei Tian; Xingli Zhao; Ping Cheng; Xiaoqian Chen; Yun Yu; Xiaochun Ding; Xueping Zhu; Zhihui Xiao
Journal:  Gastroenterol Res Pract       Date:  2016-06-08       Impact factor: 2.260

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.